The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

It’s important to note that weight loss can be a symptom of a serious infection, which is a rare side effect that Skyrizi may cause. If you experience unexplained weight loss while using the ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

So, on February 7, 2025, the FDA approved Emblaveo in combination with metronidazole for the treatment of patients with complicated intra-abdominal infections. Also, a week later, it signed a deal ...

The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat ... as well as diagnosis of infections and diseases; and ...

The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat ... as well as diagnosis of infections and diseases; and ...

The company needs Rinvoq and another new immunology drug – recently-approved psoriasis therapy Skyrizi (risankizumab) – to help offset the expected declines in Humira sales once biosimilar ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an idea of how much the field has changed, clinical guidelines on psoriasis ...

J&J said the drug was also generally well-tolerated, with the most frequently reported adverse reactions nasopharyngitis and upper respiratory tract infections and no new safety signals emerging ...